Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Mehta, Nehal N. [2 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, M. Alan [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15960
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [31] Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
    Egeberg, Alexander
    Jullien, Denis
    Du Jardin, Kristian Gaarn
    Thaci, Diamant
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [32] Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
    Thaci, D.
    Piaserico, S.
    Warren, R. B.
    Gupta, A. K.
    Cantrell, W.
    Draelos, Z.
    Foley, P.
    Igarashi, A.
    Langley, R. G.
    Asahina, A.
    Young, M.
    Falques, M.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 323 - 334
  • [33] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [34] During the Treatment with Tildrakizumab 100 mg in Patients who achieved PASI <3 at Week 28, the high Treatment Response is maintained for 5 Years: Pooled Analysis of the Studies reSURFACE 1 and reSURFACE 2
    Augustin, M.
    Diemert, S.
    Pau-Charles, I
    Thaci, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 59 - 60
  • [35] Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    DERMATOLOGY, 2022, 238 (05) : 910 - 918
  • [36] Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
    Igarashi, Atsuyuki
    Nakagawa, Hidemi
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Imafuku, Shinichi
    Tada, Yayoi
    Honma, Masaru
    Mendelsohn, Alan M.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 853 - 863
  • [37] Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions of 2 phase 3 studies
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Papp, K. A.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 110 - 111
  • [38] Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
    Reich, Kristian
    Carrascosa, Jose-Manuel
    Fumero, Emilio
    Schoenenberger Lopez, Andreu
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB11 - AB11
  • [39] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108
  • [40] Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or non-responders to etanercept: results from the reSURFACE 2 phase 3 trial through 148 weeks
    Iversen, L.
    Reich, K.
    Griffiths, C.
    Peserico, A.
    Kimball, A.
    Pau-Charles, I.
    Blauvelt, A.
    Thaci, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 56 - 56
12345